Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James Rock
AriBio Co., Ltd.
Study Director - Sharon Sha, MD, MS
Stanford University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
198 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centricity Research - Halifax
Halifax, Canada
- Okanagan Clinical Trials
Kelowna, Canada
- Parkwood Institute
London, Canada
- Baycrest Academy for Research and Education
North York, Canada
- Kawartha Centre - Redefining Healthy Aging
Peterborough, Canada
- Centricity Research
Toronto, Canada
- Sunnybrook Health Sciences Centre
Toronto, Canada
- University Health Network-Toronto Western Hospital
Toronto, Canada
- Royal Jubilee Hospital
Victoria, Canada
- Medical Arts Health Research Group - West Vancouver
West Vancouver, Canada
- Beijing Anding Hospital Capital Medical University
Beijing, China
- Beijing Friendship Hospital,capital Medical University
Beijing, China
- Beijing Tiantan Hospital, Capital Medical University
Beijing, China
- Peking Union Medical College Hospital
Beijing, China
- Peking University Sixth Hospital
Beijing, China
- Xuanwu Hospital Capital Medical University
Beijing, China
- the First Hospital of Jilin University
Changchun, China
- Xiangya Hospital of Central South University
Changsha, China
- the First Affiliated Hospital of Chongqing Medical University
Chongqing, China
- Guangdong Provincial People'S Hospital
Guangzhou, China
- the Affiliated Brain Hospital of Guangzhou Medical University
Guangzhou, China
- the First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, China
- Anhui Provincial Hospital
Hefei, China
- Tianjin Medical University General Hospital
Heping, China
- the Second Affiliated Hospital of Nanchang University
Nanchang, China
- Nanjing Drum Tower Hospital
Nanjing, China
- the Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
- Huashan Hospital Affiliated To Fudan University
Shanghai, China
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
- the First Hospital of Hebei Medical University
Shijiazhuang, China
- the First Affiliated Hospital of Soochow University
Suzhou, China
- the Second Affiliated Hospital of Soochow University
Suzhou, China
- Tongji Hospital of Tongji University
Wuhan, China
- Xuzhou Central Hospital
Xuzhou, China
- Fakultni Nemocnice U Sv. Anny V Brne
Brno, Czechia
- Neurohk S.R.O.
Choceň, Czechia
- Fakultni Nemocnice Hradec Kralove
Hradec Králové, Czechia
- Ambulance Smrkova Ulice (a-Shine S.R.O.)
Pilsen, Czechia
- Forbeli S.R.O
Prague, Czechia
- Inep Medical S.R.O.
Prague, Czechia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Dec 2022
- Primary completion
- 31 May 2026
- Completion
- 31 Dec 2027
- Last update posted
- 2 Oct 2025
- Registered enrollment
- 1,535
- Registry id
- NCT05531526
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.